Annovis Bio (ANVS) Accounts Payables (2019 - 2026)
Annovis Bio (ANVS) posted Accounts Payables of $5.3 million for Q1 2026, up 103.65% sequentially from $2.6 million in Q4 2025, and up 285.03% YoY from $1.4 million in Q1 2025.
Annovis Bio (ANVS) Accounts Payables (2019 - 2026) Analysis & Trends
Annovis Bio has reported Accounts Payables for 8 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Accounts Payables rose 285.03% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 285.03% YoY) and the FY2025 annual result came in at $2.6 million, up 12.34% from the prior year.
- Accounts Payables advanced to $5.3 million in Q1 2026 per ANVS's latest filing, from $2.6 million in the prior quarter.
- Over five years, Accounts Payables peaked at $5.3 million in Q1 2026 and troughed at $901841.0 in Q2 2022.
- A 5-year average of $2.5 million and a median of $2.1 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 685.38% in 2022, then sank 71.3% in 2025.
- Over 5 years, Accounts Payables stood at $4.0 million in 2022, then plunged by 67.36% to $1.3 million in 2023, then jumped by 78.37% to $2.3 million in 2024, then grew by 12.34% to $2.6 million in 2025, then soared by 103.65% to $5.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $5.3 million, $2.6 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 3.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.28 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 974,311.00 |
| Mar 31, 2025 | 1.37 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Mar 31, 2024 | 4.11 Mn |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 3.96 Mn |
| Sep 30, 2022 | 1.85 Mn |
| Jun 30, 2022 | 901,841.00 |
| Mar 31, 2022 | 928,997.00 |
| Dec 31, 2021 | 688,074.00 |
| Sep 30, 2021 | 289,742.00 |
| Jun 30, 2021 | 114,828.00 |